VKAs

DRUG4 trials

Sponsors

Bayer, Pfizer, Canisius Wilhelmina Ziekenhuis

Conditions

Atrial FibrillationElastin-degradation vitamin K deficiencyMajor BleedingNon-Valvular Atrial FibrillationStrokeSystemic Embolism

Unknown Phase

Anticoagulation Preference by AF Patients Study

CompletedNCT02607371

BayerAtrial Fibrillation

Start: 2015-08-27End: 2016-10-15Updated: 2017-09-14

The effects of discontinuation of vitamin K antagonists on the rate of elastin degradation

Active, not recruitingNL-OMON45726

Canisius Wilhelmina ZiekenhuisElastin-degradation vitamin K deficiency

Start: 2017-04-01Target: 100Updated: 2024-02-28

Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists

CompletedNCT04297072

BayerNon-Valvular Atrial Fibrillation

Start: 2020-05-01End: 2021-02-28Updated: 2021-03-03

NOAC Portuguese Real World Study

WithdrawnNCT04808934

PfizerMajor Bleeding, Stroke, Systemic Embolism

Start: 2020-06-01End: 2020-12-01Updated: 2023-04-05